ALPHAEON Completes Reorganization to Streamline its Corporate Structure
On January 10th, Stradling client ALPHAEON completed a reorganization to simplify its corporate structure. The company has split into two business units and each will retain the same shareholder base that was in place prior to the split off. ALPHAEON has been renamed AEON Biopharma. AEON Biopharma will focus on developing its proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions.
